Growth-factor Reduced Matrigel Source Influences Stem Cell Derived Brain Microvascular Endothelial Cell Barrier Properties

Overview

Journal Fluids Barriers CNS

Publisher Biomed Central

Date 2016 Apr 13

PMID 27068644

Citations 22

Authors

Ronak Patel

Abraham J Alahmad

Affiliations

Soon will be listed here.

Abstract

Background: Patient-derived induced pluripotent stem cells (iPSCs) are an innovative source as an in vitro model for neurological diseases. Recent studies have demonstrated the differentiation of brain microvascular endothelial cells (BMECs) from various stem cell sources, including iPSC lines. However, the impact of the culturing conditions used to maintain such stem cell pluripotency on their ability to differentiate into BMECs remains undocumented. In this study, we investigated the effect of different sources of Matrigel and stem cell maintenance medium on BMEC differentiation efficiency.

Methods: The IMR90-c4 iPSC line was maintained on mTeSR1 or in essential-8 (E-8) medium on growth factor-reduced (GFR) Matrigel from three different manufacturers. Cells were differentiated into BMECs following published protocols. The phenotype of BMEC monolayers was assessed by immunocytochemistry. Barrier function was assessed by transendothelial electrical resistance (TEER) and permeability to sodium fluorescein, whereas the presence of drug efflux pumps was assessed by uptake assay using fluorescent substrates.

Results: Stem cell maintenance medium had little effect on the yield and barrier phenotype of IMR90-derived BMECs. The source of GFR-Matrigel used for the differentiation process significantly impacted the ability of IMR90-derived BMECs to form tight monolayers, as measured by TEER and fluorescein permeability. However, the Matrigel source had minimal effect on BMEC phenotype and drug efflux pump activity.

Conclusion: This study supports the ability to differentiate BMECs from iPSCs grown in mTeSR1 or E-8 medium and also suggests that the origin of GFR-Matrigel has a marked inpact on BMEC barrier properties.

Citing Articles

The Progress in Molecular Transport and Therapeutic Development in Human Blood-Brain Barrier Models in Neurological Disorders.

Korszun-Karbowniczak J, Krysiak Z, Saluk J, Niemcewicz M, Zdanowski R Cell Mol Neurobiol. 2024; 44(1):34.

PMID: 38627312 PMC: 11021242. DOI: 10.1007/s10571-024-01473-6.

Generation of Brain Microvascular Endothelial-like Cells from Human iPS Cell-Derived Endothelial Progenitor Cells Using TGF-β Receptor Inhibitor, Laminin 511 Fragment, and Neuronal Cell Culture Supplements.

Aoki H, Yamashita M, Hashita T, Iwao T, Aoyama M, Matsunaga T Pharmaceutics. 2022; 14(12).

PMID: 36559191 PMC: 9785586. DOI: 10.3390/pharmaceutics14122697.

Brain microvascular endothelial cell dysfunction in an isogenic juvenile iPSC model of Huntington's disease.

Linville R, Nerenberg R, Grifno G, Arevalo D, Guo Z, Searson P Fluids Barriers CNS. 2022; 19(1):54.

PMID: 35773691 PMC: 9245306. DOI: 10.1186/s12987-022-00347-7.

In Vitro Models of the Human Blood-Brain Barrier Utilising Human Induced Pluripotent Stem Cells: Opportunities and Challenges.

Pervaiz I, Al-Ahmad A Methods Mol Biol. 2022; 2492:53-72.

PMID: 35733038 DOI: 10.1007/978-1-0716-2289-6_3.

Three-Dimensional Models of Healthy and Tumor Brain Microvasculature for Drug and Toxicity Screening.

Piantino M, Figarol A, Matsusaki M Front Toxicol. 2022; 3:656254.

PMID: 35295158 PMC: 8915870. DOI: 10.3389/ftox.2021.656254.

References

Blanchette M, Daneman R . Formation and maintenance of the BBB. Mech Dev. 2015; 138 Pt 1:8-16. DOI: 10.1016/j.mod.2015.07.007. View

Cygalova L, Hofman J, Ceckova M, Staud F . Transplacental pharmacokinetics of glyburide, rhodamine 123, and BODIPY FL prazosin: effect of drug efflux transporters and lipid solubility. J Pharmacol Exp Ther. 2009; 331(3):1118-25. DOI: 10.1124/jpet.109.160564. View

Zhao Z, Sagare A, Ma Q, Halliday M, Kong P, Kisler K . Central role for PICALM in amyloid-β blood-brain barrier transcytosis and clearance. Nat Neurosci. 2015; 18(7):978-87. PMC: 4482781. DOI: 10.1038/nn.4025. View

Emonard H, Grimaud J, Nusgens B, Lapiere C, Foidart J . Reconstituted basement-membrane matrix modulates fibroblast activities in vitro. J Cell Physiol. 1987; 133(1):95-102. DOI: 10.1002/jcp.1041330112. View

Poller B, Gutmann H, Krahenbuhl S, Weksler B, Romero I, Couraud P . The human brain endothelial cell line hCMEC/D3 as a human blood-brain barrier model for drug transport studies. J Neurochem. 2008; 107(5):1358-68. DOI: 10.1111/j.1471-4159.2008.05730.x. View

Perriere N, Demeuse P, Garcia E, Regina A, Debray M, Andreux J . Puromycin-based purification of rat brain capillary endothelial cell cultures. Effect on the expression of blood-brain barrier-specific properties. J Neurochem. 2005; 93(2):279-89. DOI: 10.1111/j.1471-4159.2004.03020.x. View

Cucullo L, Couraud P, Weksler B, Romero I, Hossain M, Rapp E . Immortalized human brain endothelial cells and flow-based vascular modeling: a marriage of convenience for rational neurovascular studies. J Cereb Blood Flow Metab. 2007; 28(2):312-28. DOI: 10.1038/sj.jcbfm.9600525. View

Wang Q, Yang H, Miller D, Elmquist W . Effect of the p-glycoprotein inhibitor, cyclosporin A, on the distribution of rhodamine-123 to the brain: an in vivo microdialysis study in freely moving rats. Biochem Biophys Res Commun. 1995; 211(3):719-26. DOI: 10.1006/bbrc.1995.1872. View

Vukicevic S, Kleinman H, Luyten F, Roberts A, Roche N, Reddi A . Identification of multiple active growth factors in basement membrane Matrigel suggests caution in interpretation of cellular activity related to extracellular matrix components. Exp Cell Res. 1992; 202(1):1-8. DOI: 10.1016/0014-4827(92)90397-q. View

10.

Palmiotti C, Prasad S, Naik P, Abul K, Sajja R, Achyuta A . In vitro cerebrovascular modeling in the 21st century: current and prospective technologies. Pharm Res. 2014; 31(12):3229-50. PMC: 4225221. DOI: 10.1007/s11095-014-1464-6. View

11.

Hughes C, Postovit L, Lajoie G . Matrigel: a complex protein mixture required for optimal growth of cell culture. Proteomics. 2010; 10(9):1886-90. DOI: 10.1002/pmic.200900758. View

12.

Yu J, Vodyanik M, Smuga-Otto K, Antosiewicz-Bourget J, Frane J, Tian S . Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007; 318(5858):1917-20. DOI: 10.1126/science.1151526. View

13.

Robey R, Honjo Y, van de Laar A, Miyake K, Regis J, Litman T . A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2). Biochim Biophys Acta. 2001; 1512(2):171-82. DOI: 10.1016/s0005-2736(01)00308-x. View

14.

Miranda C, Reed R, Kuiper H, Alber S, Stevens J . Ascorbic acid promotes detoxification and elimination of 4-hydroxy-2(E)-nonenal in human monocytic THP-1 cells. Chem Res Toxicol. 2009; 22(5):863-74. PMC: 2730585. DOI: 10.1021/tx900042u. View

15.

Parent J, Anderson S . Reprogramming patient-derived cells to study the epilepsies. Nat Neurosci. 2015; 18(3):360-6. PMC: 4483308. DOI: 10.1038/nn.3944. View

16.

Beevers J, Caffrey T, Wade-Martins R . Induced pluripotent stem cell (iPSC)-derived dopaminergic models of Parkinson's disease. Biochem Soc Trans. 2013; 41(6):1503-8. DOI: 10.1042/BST20130194. View

17.

Zeng X, Hunsberger J, Simeonov A, Malik N, Pei Y, Rao M . Concise review: modeling central nervous system diseases using induced pluripotent stem cells. Stem Cells Transl Med. 2014; 3(12):1418-28. PMC: 4250211. DOI: 10.5966/sctm.2014-0102. View

18.

Lippmann E, Azarin S, Kay J, Nessler R, Wilson H, Al-Ahmad A . Derivation of blood-brain barrier endothelial cells from human pluripotent stem cells. Nat Biotechnol. 2012; 30(8):783-91. PMC: 3467331. DOI: 10.1038/nbt.2247. View

19.

Chen G, Gulbranson D, Hou Z, Bolin J, Ruotti V, Probasco M . Chemically defined conditions for human iPSC derivation and culture. Nat Methods. 2011; 8(5):424-9. PMC: 3084903. DOI: 10.1038/nmeth.1593. View

20.

Wilson H, Canfield S, Hjortness M, Palecek S, Shusta E . Exploring the effects of cell seeding density on the differentiation of human pluripotent stem cells to brain microvascular endothelial cells. Fluids Barriers CNS. 2015; 12:13. PMC: 4455681. DOI: 10.1186/s12987-015-0007-9. View